Highlight
KRAS mutations, especially non-G12C subtypes, represent a significant challenge in NSCLC targeted therapy due to limited effective options.
MEK inhibitor trametinib induces adaptive resistance via feedback activation of multiple receptor tyrosine kinases (RTKs).
